Obead Yaseen, M.D., FRCPC, FASN

Obead Yaseen, M.D., FRCPC, FASN

M.D., Assistant Professor (Clinician-Educator), Nephrology and Hypertension Fellowship Program Director, Medical Fellow/Resident/Student Instruction

obead.yaseen@wayne.edu

313-745-7145

313-745-8041 (fax)

Obead Yaseen, M.D., FRCPC, FASN

Office Address

4160 John R, Harper Professional Building #908, Detroit, Michigan 48201

Biography

 LICENSURE AND CERTIFICATION
• Fellow of Royal College of Physicians and Surgeons of Canada
(FRCPC)/Nephrology
• American Board of Nephrology Certified
• Fellow of Royal College of Physicians and Surgeons of Canada (FRCPC)/Internal
Medicine
• American Board of Internal Medicine Certified (ABIM)
• Licentiate of the Medical Council of Canada (LMCC)

Education Training

 FELLOWSHIP
JULY 2016 – JUN 2018 Wayne State University / Detroit Medical Center - USA
• Nephrology Fellow
• Chief Fellow (July 2017-JUN 2018)
• American Board of Nephrology Certified

RESIDENCY
JULY 2013 – JUN 2016 Wayne State University / Detroit Medical Center
Sinai Grace Hospital - USA
• Internal Medicine Resident
• American Board of Internal Medicine Certified (ABIM)

EDUCATION
SEPT 2000 – AUG 2007 Misr University for Science and Technology (MUST) – Egypt
• Bachelor of Medicine and Bachelor of Surgery (M. B., Bch.)

Medical

JULY 2019– Present Member of Royal College of Physicians and Surgeons of Canada
(RCPSC)
JULY 2018 – Present Member of College of Physicians and Surgeons of Ontario (CPSO)
MAY 2018 – Present Member of American Society of Hypertension (ASH)
JULY 2016– Present Member of American Society of Nephrology (ASN)
JULY 2016– Present Member of National Kidney Foundation (NKF)
JULY 2013– Present Member of American College of Physicians (ACP)

Research

OCT 2014 – JUN 2016 HOTEL DIEU GRACE HOSPITAL – Ontario, Canada
• Randomized clinical trial funded by the Kidney Foundation of Canada. This is a follow up
study for the retrospective cohort study performed during June 2011 – June 2012.
• To determine the Efficacy of Low Dose Versus High Dose Alteplase (tPA) in Restoring
Hemodialysis Catheter Dysfunction
• Randomized clinical trial concluded, recently, results accepted as a poster presentation in
the American Society of Nephrology Kidney Week 2017 Annual Meeting.
• Mentor: Dr. Albert Kadri, MD, FRCPC


JUNE 2011 – June 2012 HOTEL DIEU GRACE HOSPITAL – Ontario, Canada
Principal Investigator
• Retrospective cohort study to determine the Efficacy of Low Dose Versus High Dose
Alteplase (tPA) in Restoring Hemodialysis Catheter Dysfunction
• Mentor: Dr. Albert Kadri, MD, FRCPC

Publications

 Retrospective Cohort study:
Yaseen O, El-Masri MM, El Nekidy WS, Soong D, Ibrahim M, Speirs JW, Kadri A.
Comparison of(tPA) high versus low dose protocol in restoring hemodialysis Catheter
function: ALTE-DOSE Study. Hemodial Int. 2013 Jul;17(3):434-40.doi:
10.111/hdi.12004.Epub 2012 Nov 26.

• Case report:
Yaseen O, El Nekidy WS, Ibrahim AR, Jasey BB, Guignard M, Kadri A. Cyclic PseudoPeritonitis Secondary to Endometriosis in PD Patient. Perit Dial Int. 2012 NovDec;32(6);662-4. doi:10.3747/pdi.2012.00099.

• Abstract:
Ravi Thimmisetty, Mohammed Omar Azam, Adekola Oritsegbubemi, Obead
Yaseen, Zeenat Yousuf Bhat, Nashat B. Imran, Yayha Osman-Malik. Success of
urgent start peritoneal dialysis in an intensive care unit. American Journal of Kidney
Diseases, Vol.69, Issue 4, B1-B16. Published in issue: April 2017.

← Return to listing